These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 26620255)

  • 1. Discovery of the imidazole-derived GPR40 agonist AM-3189.
    Ma Z; Lin DC; Sharma R; Liu J; Zhu L; Li AR; Kohn T; Wang Y; Liu JJ; Bartberger MD; Medina JC; Zhuang R; Li F; Zhang J; Luo J; Wong S; Tonn GR; Houze JB
    Bioorg Med Chem Lett; 2016 Jan; 26(1):15-20. PubMed ID: 26620255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel orally bioavailable GPR40 agonists.
    Lu H; Fei H; Yang F; Zheng S; Hu Q; Zhang L; Yuan J; Feng J; Sun P; Dong Q
    Bioorg Med Chem Lett; 2013 May; 23(10):2920-4. PubMed ID: 23582779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N
    Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a novel potent GPR40 full agonist.
    Meegalla SK; Huang H; Martin T; Xu J; Zhao S; Liu J; Hall M; Gunnet J; Wang Y; Rady B; Silva J; Otieno M; Arnoult E; Paul Lee S; Pocai A; Player MR
    Bioorg Med Chem Lett; 2018 Feb; 28(4):720-726. PubMed ID: 29366647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR40 agonists.
    Huang H; Winters MP; Meegalla SK; Arnoult E; Paul Lee S; Zhao S; Martin T; Rady B; Liu J; Towers M; Otieno M; Xu F; Lim HK; Silva J; Pocai A; Player MR
    Bioorg Med Chem Lett; 2018 Feb; 28(3):429-436. PubMed ID: 29258772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMG 837: a potent, orally bioavailable GPR40 agonist.
    Houze JB; Zhu L; Sun Y; Akerman M; Qiu W; Zhang AJ; Sharma R; Schmitt M; Wang Y; Liu J; Liu J; Medina JC; Reagan JD; Luo J; Tonn G; Zhang J; Lu JY; Chen M; Lopez E; Nguyen K; Yang L; Tang L; Tian H; Shuttleworth SJ; Lin DC
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1267-70. PubMed ID: 22217876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of GPR40 Agonists for Type 2 Diabetes.
    Liu JJ; Wang Y; Ma Z; Schmitt M; Zhu L; Brown SP; Dransfield PJ; Sun Y; Sharma R; Guo Q; Zhuang R; Zhang J; Luo J; Tonn GR; Wong S; Swaminath G; Medina JC; Lin DC; Houze JB
    ACS Med Chem Lett; 2014 May; 5(5):517-21. PubMed ID: 24900872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes.
    Winters MP; Sui Z; Wall M; Wang Y; Gunnet J; Leonard J; Hua H; Yan W; Suckow A; Bell A; Clapper W; Jenkinson C; Haug P; Koudriakova T; Huebert N; Murray WV
    Bioorg Med Chem Lett; 2018 Mar; 28(5):841-846. PubMed ID: 29456108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
    Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A
    J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and structure-activity relationship studies of GPR40 agonists containing amide linker.
    Chen T; Ning M; Ye Y; Wang K; Leng Y; Shen J
    Eur J Med Chem; 2018 May; 152():175-194. PubMed ID: 29705709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and optimization of 5-(2-((1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)oxy)pyridin-4-yl)-1,2,4-oxadiazoles as novel gpr119 agonists.
    Wang Y; Yu M; Zhu J; Zhang JK; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Liu JJ; Coward P
    Bioorg Med Chem Lett; 2014 Feb; 24(4):1133-7. PubMed ID: 24440299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.
    Brown SP; Dransfield PJ; Vimolratana M; Jiao X; Zhu L; Pattaropong V; Sun Y; Liu J; Luo J; Zhang J; Wong S; Zhuang R; Guo Q; Li F; Medina JC; Swaminath G; Lin DC; Houze JB
    ACS Med Chem Lett; 2012 Sep; 3(9):726-30. PubMed ID: 24900539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of diacylphloroglucinols as a new class of GPR40 (FFAR1) agonists.
    Bharate SB; Rodge A; Joshi RK; Kaur J; Srinivasan S; Kumar SS; Kulkarni-Almeida A; Balachandran S; Balakrishnan A; Vishwakarma RA
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6357-61. PubMed ID: 18993064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability.
    Christiansen E; Due-Hansen ME; Urban C; Grundmann M; Schmidt J; Hansen SV; Hudson BD; Zaibi M; Markussen SB; Hagesaether E; Milligan G; Cawthorne MA; Kostenis E; Kassack MU; Ulven T
    J Med Chem; 2013 Feb; 56(3):982-92. PubMed ID: 23294321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and structure-activity-relationship of phenyl imidazoles as potent Smoothened antagonists.
    Cheng D; Han D; Gao W; Jing Q; Jiang J; Wan Y; Englund NP; Tuntland T; Wu X; Pan S
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6573-6. PubMed ID: 23036954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles.
    Wang Y; Liu JJ; Dransfield PJ; Zhu L; Wang Z; Du X; Jiao X; Su Y; Li AR; Brown SP; Kasparian A; Vimolratana M; Yu M; Pattaropong V; Houze JB; Swaminath G; Tran T; Nguyen K; Guo Q; Zhang J; Zhuang R; Li F; Miao L; Bartberger MD; Correll TL; Chow D; Wong S; Luo J; Lin DC; Medina JC
    ACS Med Chem Lett; 2013 Jun; 4(6):551-5. PubMed ID: 24900707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.
    Bazydlo-Guzenda K; Buda P; Mach M; Pieczykolan J; Kozlowska I; Janiszewski M; Drzazga E; Dominowski J; Ziolkowski H; Wieczorek M; Gad SC
    PLoS One; 2021; 16(9):e0257477. PubMed ID: 34555055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and evaluation of 1-benzyl-1H-imidazole-5-carboxamide derivatives as potent TGR5 agonists.
    Zhao S; Li X; Wang L; Peng W; Ye W; Li W; Wang YD; Chen WD
    Bioorg Med Chem; 2021 Feb; 32():115972. PubMed ID: 33440321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators.
    Chae E; Shin YJ; Ryu EJ; Ji MK; Ryune Cho N; Lee KH; Jeong HJ; Kim SJ; Choi Y; Seok Oh K; Park CE; Soo Yoon Y
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2134-9. PubMed ID: 23434029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus.
    Hamdouchi C; Maiti P; Warshawsky AM; DeBaillie AC; Otto KA; Wilbur KL; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Cr S; Lineswala JP; Neathery GL; Bouaichi C; Diseroad BA; Campbell AN; Sweetana SA; Adams LA; Cabrera O; Ma X; Yumibe NP; Montrose-Rafizadeh C; Chen Y; Miller AR
    J Med Chem; 2018 Feb; 61(3):934-945. PubMed ID: 29236497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.